Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the LANDMARK trial
- Published on 03/27/2024
- Reading time: 4 min.
Masanori Kato 1, Hidetoshi Ito 1, Akane Yamakawa 2, Tatsuo Kagimura 2, Masafumi Fukagawa 3, Masahiro Yamamoto 1, Yoshinori Saito 1, Tadao Akizawa 4, Hiroaki Ogata 1,5
1
Division of Nephrology, Department of Internal Medicine
Showa University Northern Yokohama Hospital
Yokohama
Kanagawa
Japan
2
The Translational Research Center for Medical Innovation
Foundation for Biomedical Research and Innovation at Kobe
Kobe
Hyogo
Japan
3
Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine
Tokai University School of Medicine
Isehara
Kanagawa
Japan
4
Division of Nephrology, Department of Medicine
Showa University Graduate School of Medicine
Shinagawa
Tokyo
Japan
5
Department of Medical Education
Showa University Graduate School of Medicine
Shinagawa
Tokyo
Japan
Abstract
Introduction The clinical benefits of aspirin in patients undergoing hemodialysis remain unclear.
Methods The secondary analysis of the LANDMARK trial investigated whether aspirin use was associated with cardiovascular events (CVEs) and all‐cause mortality was performed. A total of 2135 patients at risk for vascular calcification were analyzed using a Cox proportional hazards model with propensity score matching.
Results The risk of...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Nephrology
Receive our newsletter to stay up to date with the latest news in Nephrology
